Compound Evidence File
#EC-2026-0418
Blend 300 (TRA/Mast P/Test P)
Filed under Injectable Oils. The bureau holds 95 laboratory returns for this compound from 35 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
35 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 8 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 7 | 10.0 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| Shanghai JinBei Chemical TechnologyCASE #VI-2026-0107 | X | 1 | 10.0 | 10.0 | 10.0 | 2 Apr 2025 | 2 Apr 2025 |
| Trusted PeptideCASE #VI-2026-0499 | X | 1 | 9.3 | 9.3 | 9.3 | 11 Jun 2025 | 11 Jun 2025 |
| Bulk Peptide SupplyCASE #VI-2026-0446 | X | 1 | 9.1 | 9.1 | 9.1 | 3 Jun 2025 | 3 Jun 2025 |
| HealthTide BiotechCASE #VI-2026-0955 | X | 1 | 9.1 | 9.1 | 9.1 | 3 Jun 2025 | 3 Jun 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 8 | 8.8 | 8.2 | 9.9 | 21 May 2026 | 21 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 4 | 8.8 | 8.4 | 9.3 | 21 May 2026 | 21 May 2026 |
| Peptide PartnersCASE #VI-2026-0295 | X | 4 | 8.6 | 6.6 | 9.9 | 16 Mar 2025 | 25 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.5 | 7.5 | 10.0 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 3 | 8.1 | 7.0 | 9.2 | 25 May 2026 | 25 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 6 | 7.9 | 6.6 | 9.4 | 23 May 2026 | 23 May 2026 |
| ZZQ PeptidesCASE #VI-2026-0550 | X | 1 | 7.9 | 7.9 | 7.9 | 7 May 2025 | 7 May 2025 |
| Xian Yihang TechnologyCASE #VI-2026-0656 | X | 2 | 7.8 | 7.6 | 7.9 | 20 Jun 2025 | 24 May 2026 |
| Heman Peptide HMCASE #VI-2026-0089 | X | 1 | 7.8 | 7.8 | 7.8 | 13 Feb 2025 | 13 Feb 2025 |
| Yabang PeptideCASE #VI-2026-0148 | X | 1 | 7.6 | 7.6 | 7.6 | 17 Dec 2024 | 17 Dec 2024 |
| PeptidologyCASE #VI-2026-0520 | X | 1 | 7.6 | 7.6 | 7.6 | 7 May 2025 | 7 May 2025 |
| Yongkang Nuoao Trading CoCASE #VI-2026-0646 | X | 1 | 7.5 | 7.5 | 7.5 | 13 Feb 2025 | 13 Feb 2025 |
| Zenith Jove Peptide ZJCASE #VI-2026-0570 | X | 2 | 7.3 | 5.7 | 8.9 | 6 May 2025 | 26 Jan 2026 |
| Xingruida XDRCASE #VI-2026-0898 | X | 6 | 6.9 | 4.0 | 8.9 | 3 Jul 2025 | 23 May 2026 |
| SRY LabsCASE #VI-2026-0657 | X | 11 | 6.7 | 4.6 | 9.3 | 9 Jun 2025 | 24 May 2026 |
| HXNetCASE #VI-2026-0061 | X | 4 | 6.3 | 4.6 | 7.6 | 11 Jun 2025 | 23 May 2026 |
| Allen Biotechnology Co ABCCASE #VI-2026-0709 | X | 2 | 6.3 | 5.7 | 7.0 | 6 May 2025 | 21 May 2026 |
| PeptiLab ResearchCASE #VI-2026-0267 | X | 1 | 6.2 | 6.2 | 6.2 | 3 Jul 2025 | 3 Jul 2025 |
| Haikou Mingheng TechnologyCASE #VI-2026-0250 | X | 1 | 6.0 | 6.0 | 6.0 | 8 Jul 2025 | 8 Jul 2025 |
| PurePEPSCASE #VI-2026-0552 | X | 1 | 5.8 | 5.8 | 5.8 | 13 Feb 2025 | 13 Feb 2025 |
| Xingtai Lesda TechnologyCASE #VI-2026-0381 | X | 1 | 5.8 | 5.8 | 5.8 | 11 Jun 2025 | 11 Jun 2025 |
| Coastal PeptidesCASE #VI-2026-0958 | X | 2 | 5.6 | 4.9 | 6.3 | 8 Jul 2025 | 17 May 2026 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 1 | 5.4 | 5.4 | 5.4 | 16 Mar 2025 | 16 Mar 2025 |
| Zen PeptidesCASE #VI-2026-0940 | X | 1 | 5.1 | 5.1 | 5.1 | 2 Jul 2025 | 2 Jul 2025 |
| Dragon PharmaCASE #VI-2026-0519 | X | 1 | 4.4 | 4.4 | 4.4 | 7 May 2025 | 7 May 2025 |
| Alimo PeptideCASE #VI-2026-0524 | X | 1 | 4.2 | 4.2 | 4.2 | 6 May 2025 | 6 May 2025 |
| Xianhong Tong XHT PeptidesCASE #VI-2026-0997 | X | 1 | 3.9 | 3.9 | 3.9 | 13 Jun 2025 | 13 Jun 2025 |
| Weifang Xingbei International TradeCASE #VI-2026-0766 | X | 1 | 1.3 | 1.3 | 1.3 | 13 Feb 2025 | 13 Feb 2025 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 0.0 | 0.0 | 0.0 | 17 Dec 2024 | 17 Dec 2024 |
Open any subject to view the batch-level evidence for Blend 300 (TRA/Mast P/Test P) alone.